Paradigm Biocapital Advisors LP Esperion Therapeutics, Inc. Transaction History

Paradigm Biocapital Advisors LP

  • $2.77 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$5.45 - $8.13 $1.7 Million - $2.53 Million
311,781 Added 22.14%
1,719,831 $11.5 Million
Q2 2022

Aug 15, 2022
BUY
$4.77 - $6.67 $1.2 Million - $1.67 Million
250,804 Added 21.67%
1,408,050 $8.96 Million
Q1 2022

May 16, 2022
BUY
$3.34 - $5.56 $1.06 Million - $1.77 Million
317,989 Added 37.89%
1,157,246 $5.37 Million
Q4 2021

Feb 14, 2022
BUY
$4.81 - $11.92 $4.04 Million - $10 Million
839,257 New
839,257 $4.2 Million

Others Institutions Holding ESPR

# of Institutions
207
Shares Held
128M
Call Options Held
1.67M
Put Options Held
930K
View Full List

About Esperion Therapeutics, Inc.

ESPR Quotes by TradingView
  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $168M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Paradigm Biocapital Advisors LP Portfolio

Follow Paradigm Biocapital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email